On September 20-21, 2016 Allison Dudley, Executive Director and David Flynn, Counsel to the Board attended an inter-governmental working meeting at the Food and Drug Administration to discuss the oversight of drug compounding and the relationship between the activities of the FDA and the states. The meeting provided an opportunity to discuss each state’s regulatory framework, recent FDA guidance documents, changes to the FDA’s inspection procedures, and information sharing challenges and opportunities.
More Latest News
January 2, 2020
Click here for the new requirements requiring prescribers to generate and transmit all prescriptions electronically Continue reading
December 16, 2019
The Quarterly Performance Report for the first quarter of the 2019-2020 fiscal year is now available online. Continue reading